Featured Question

If a patient with a common EGFR mutation (eg, exon 19 or 20) shows apparent resistance to EGFR TKIs, how do you approach further testing to look for a secondary mutation that might explain the resistance?

See The Answer

Get the latest
science delivered
to your inbox

Answers in CME updates are
available in YOUR specialty.

Sign-up Now!

Featured Activities


Assessing the Evolving Therapeutic Landscape in Advanced Prostate Cancer: Where Do We Stand?

Course Director
Oliver Sartor, MD
Tulane Cancer Center
Tulane University School of Medicine
New Orleans, Louisiana


Current Perspectives and Emerging Directions in Molecular Testing for Lung Cancer

Course Director
Anjali Saqi, MD
Columbia University Medical Center
New York, New York

Photo Courtesy of
Columbia Technology Ventures


Challenging Cases in Multiple Sclerosis

Course Director
Aaron E. Miller, MD
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine
New York, New York